Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab for GVHD Prevention After Double Unit Cord Blood Transplantation
NCT03434730Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Feb 2018
- Primary completion
- Apr 2025
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of tocilizumab in graft-versus-host disease (GVHD), sponsored by Memorial Sloan Kettering Cancer Center. Started Feb 2018; status: completed.
02
Drugs
tocilizumab
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT03434730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03434730.